Cargando…
Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/ https://www.ncbi.nlm.nih.gov/pubmed/36016189 http://dx.doi.org/10.3390/vaccines10081301 |
_version_ | 1784776097603256320 |
---|---|
author | López-Marte, Paola Soto-González, Alondra Ramos-Tollinchi, Lizzie Torres-Jorge, Stephan Ferre, Mariana Rodríguez-Martinó, Esteban Torres, Esther A. Sariol, Carlos A. |
author_facet | López-Marte, Paola Soto-González, Alondra Ramos-Tollinchi, Lizzie Torres-Jorge, Stephan Ferre, Mariana Rodríguez-Martinó, Esteban Torres, Esther A. Sariol, Carlos A. |
author_sort | López-Marte, Paola |
collection | PubMed |
description | Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity. |
format | Online Article Text |
id | pubmed-9414888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94148882022-08-27 Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose López-Marte, Paola Soto-González, Alondra Ramos-Tollinchi, Lizzie Torres-Jorge, Stephan Ferre, Mariana Rodríguez-Martinó, Esteban Torres, Esther A. Sariol, Carlos A. Vaccines (Basel) Article Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity. MDPI 2022-08-11 /pmc/articles/PMC9414888/ /pubmed/36016189 http://dx.doi.org/10.3390/vaccines10081301 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article López-Marte, Paola Soto-González, Alondra Ramos-Tollinchi, Lizzie Torres-Jorge, Stephan Ferre, Mariana Rodríguez-Martinó, Esteban Torres, Esther A. Sariol, Carlos A. Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title | Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title_full | Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title_fullStr | Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title_full_unstemmed | Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title_short | Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose |
title_sort | inefficient induction of neutralizing antibodies against sars-cov-2 variants in patients with inflammatory bowel disease on anti-tumor necrosis factor therapy after receiving a third mrna vaccine dose |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/ https://www.ncbi.nlm.nih.gov/pubmed/36016189 http://dx.doi.org/10.3390/vaccines10081301 |
work_keys_str_mv | AT lopezmartepaola inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT sotogonzalezalondra inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT ramostollinchilizzie inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT torresjorgestephan inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT ferremariana inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT rodriguezmartinoesteban inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT torresesthera inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose AT sariolcarlosa inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose |